Genmab A (GMAB) Current Taxes (2018 - 2026)
Genmab A (GMAB) reported Current Taxes of -$21.0 million for Q1 2026, up 57.14% on a YoY basis from -$13.4 million in Q1 2025, and down 148.84% quarter-over-quarter from $43.0 million in Q4 2025.
Genmab A (GMAB) Current Taxes (2018 - 2026) Analysis & Trends
Genmab A has reported Current Taxes for 7 years, with the latest figure at -$21.0 million in Q1 2026.
- For the quarter ending Q1 2026, Current Taxes rose 57.14% year-over-year to -$21.0 million; the trailing twelve-month figure through Mar 2026 stood at -$21.0 million (up 57.14% YoY), and the FY2025 full-year result was $43.0 million, down 82.01% from the prior year.
- Current Taxes for Q1 2026 stood at -$21.0 million, down from $43.0 million in the prior quarter.
- The five-year high for Current Taxes was $239.0 million in Q4 2024, with the low at -$228.0 million in Q3 2024.
- Historically, Current Taxes has averaged -$57.9 million across 4 years, with a median of -$53.0 million in 2024.
- Annual changes were most pronounced in 2024 — Current Taxes surged 2887.5% — and 2025, when it sank 82.01%.
- Genmab A's Current Taxes stood at $8.0 million in 2023, then surged by 2887.5% to $239.0 million in 2024, then slumped by 82.01% to $43.0 million in 2025, then slumped by 148.84% to -$21.0 million in 2026.
- The last three Current Taxes figures came in at -$21.0 million (Q1 2026), $43.0 million (Q4 2025), and -$217.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | 10,460.56 |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 19.20 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | - |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | - |
| 10 | Genmab A | 48.34 Bn | 46.82 Bn | 831.00 Mn | -21.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -21.00 Mn |
| Dec 31, 2025 | 43.00 Mn |
| Sep 30, 2025 | -217.00 Mn |
| Jun 30, 2025 | -136.00 Mn |
| Mar 31, 2025 | -49.00 Mn |
| Dec 31, 2024 | 239.00 Mn |
| Sep 30, 2024 | -228.00 Mn |
| Jun 30, 2024 | -161.00 Mn |
| Mar 31, 2024 | -57.00 Mn |
| Dec 31, 2023 | 8.00 Mn |
| Sep 30, 2020 | -1,176.00 |
| Dec 31, 2019 | -162.00 |
| Sep 30, 2019 | -210.00 |
| Dec 31, 2018 | -51.42 Mn |